You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

DENO

Cancer Type: Genitourinary, Prostate      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
New Drug Funding Program
    Denosumab - Hormone Refractory Prostate Cancer
Exceptional Access Program
    denosumab - Bony metastases in hormone refractory prostate cancer, with specific criteria

You might also be interested in